Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Rapid Therapeutic Science Laboratories, Inc. (RTSL)
Dallas, TX, US
Rapid Therapeutic Science Laboratories, Inc. (RTSL) is a biotechnology firm specializing in the aerosolized delivery of non-psychoactive cannabinoids directly into the bloodstream. This innovative approach is aimed at treating various conditions, including chronic pain, post-traumatic stress disorder (PTSD), insomnia, and aiding in surgery recovery, among other health issues. RTSL's product portfolio features pressurized meter dose inhalers (MDIs), designed to precisely dispense an aerosolized mist into the lungs, alongside sublingual oral spray devices. Furthermore, the company offers water-soluble cannabidiol (CBD) and cannabigerol (CBG) isolates under its "nhaler" brand. Established in 2013 and based in Dallas, Texas, the company adopted its current name, Rapid Therapeutic Science Laboratories, Inc., in January 2020, having previously operated as Holly Brothers Pictures, Inc. It was also formerly a subsidiary of Texas Mdi, Inc.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +200.00% | +300.00% | -14.29% | -90.77% | -98.44% | -99.60% | -99.60% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Devices: +11.2%—
-
EPS growth Medical - Devices: +28.5%+95.7% ★ Q4'24: +97.6% (vs Q3'22)
-
FCF margin FCF growth · Medical - Devices: +30.9%—
-
EBIT margin Medical - Devices: +6.2%—
-
ROIC Medical - Devices: +3.3%-23.0% Q4'24: -10.4% (vs Q3'22)
-
Share dilution Medical - Devices: 0.0%+149.1% Q4'24: -100.0% (vs Q3'22)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-58.18× Q4'24: -254.15× (vs Q3'22)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Dan F. Boone | 15.40M | 8.50% | — | 15.40M | — | — | IN | United States | 2021-01-25 | ↗ |
| 2 | Armistice Capital, LLC | 1.49M | 7.04% | — | 1.49M | — | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 3 | Steven Boyd | 1.49M | 7.04% | — | 1.49M | — | — | HC, IN | Delaware | 2024-02-14 | ↗ |
| 4 | Brent Willson | 750.0K | 62.30% | 750.0K | — | 750.0K | 10.00 | IN | USA | 2018-02-22 | ↗ |
| 5 | Steve Bond | 250.0K | 20.80% | 250.0K | — | 250.0K | 10.00 | IN | USA | 2018-02-22 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-27 | Schmidt Donal Ray Jr. | Director / Officer / 10% Owner | G-Gift | D | Common Stock | 2,000,000 | 0.26 | 520.0K | 48,333,333 | — | ↗ |
| 2021-12-27 | Berrier Sean Paul | 10% Owner | G-Gift | D | Common Stock | 2,000,000 | 0.26 | 520.0K | 48,333,333 | — | ↗ |
| 2021-08-27 | Punzi Henry Anthony | Director | — | D | Common Stock | 0 | 0.00 | — | 62,500 | — | ↗ |
| 2021-08-03 | Justin Scott Suggs | Director | — | D | Common Stock | 0 | 0.00 | — | 2,903,228 | — | ↗ |
| 2020-12-28 | Schmidt Donal Ray Jr. | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 2,000,000 | 0.25 | 500.0K | 50,933,333 | — | ↗ |
| 2020-12-28 | Berrier Sean Paul | 10% Owner | S-Sale | D | Common Stock | 600,000 | 0.25 | 150.0K | 50,333,333 | — | ↗ |
| 2020-12-22 | Schmidt Donal Ray Jr. | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 600,000 | 0.25 | 150.0K | 50,333,333 | — | ↗ |
| 2020-12-22 | Berrier Sean Paul | 10% Owner | S-Sale | D | Common Stock | 2,000,000 | 0.25 | 500.0K | 50,933,333 | — | ↗ |
| 2020-12-02 | Schmidt Donal Ray Jr. | Director / Officer / 10% Owner | J-Other | D | Common Stock | 140,000,000 | 0.00 | — | 0 | — | ↗ |
| 2020-12-02 | Berrier Sean Paul | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 54,600,000 | — | ↗ |
| 2020-11-15 | Schmidt Donal Ray Jr. | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 140,000,000 | — | ↗ |
| 2019-11-22 | Texas MDI, Inc. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 140,000,000 | — | ↗ |
| 2019-11-15 | WATLER D HUGHES | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-01-29 | Willson Brent | Director / Officer / 10% Owner | A-Award | A | Common Stock | 750,000 | 0.00 | 750.00 | 750,000 | — | ↗ |
| 2018-01-29 | Bond Steve | Director / Officer / 10% Owner | A-Award | A | Common Stock | 250,000 | 0.00 | 250.00 | 250,000 | — | ↗ |
| 2018-01-25 | Willson Brent | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-01-25 | Bond Steve | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| D. Hughes Watler Jr. | Chief Financial Officer & Director | 37.6K | male |
| Donal R. Schmidt Jr. | President, Chief Executive Officer & Chairman | — | male |
| Duane Drinkwine | Chief Science Officer | — | — |
| Frank Gill | Chief Isolate Laboratory Technician | — | male |
| Ryan C. Johnson | Vice President of Marketing | — | male |
| Sean Paul Berrier | Senior Vice President | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RTSL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
